Endocrine Abstracts

Background: Hypercalciuria is frequent in patients with acromegaly, but it is unclear how GH/insulin-like growth factor 1 (IGF1) regulate renal calcium handling. Elevated fasting plasma calcium levels despite increased glomerular filtration suggest enhanced renal calcium reabsorption.Objective: To investigate the impact of acromegaly on phosphocalcium metabolism.Design: Prospective sequential study (ClinicalTrials.gov Identifier: N...

Context: The effects of cabergoline on cardiac valves have been extensively studied in Parkinson’s disease and hyperprolactinemia but not in acromegaly, a condition at risk of cardiac valve abnormalities.Objective: We examined the prevalence of heart valve disease and regurgitation in a series of patients with acromegaly treated with cabergoline, by comparison with matched patients who had never received this drug.Design and s...

Background: Mitotane antitumor efficacy is related to plasma levels. Objective responses have been associated with mitotane plasma levels >14 mg/l. However, high plasma levels >20 or >30 mg/l are at higher risk of toxicity, especially neurotoxicity. National-based survey is lacking to evaluate the frequency and severity of high mitotane plasma levels. Our aim was to retrospectively describe serious adverse events (SAE).Methods: Mitotane plasm...

Introduction: Recombinant human parathyroid hormone (rPTH) (1–34) is prescribed off-label in France for patients with hypoparathyroidism resistant to conventional therapy. However, the bone impact of this long-term replacement therapy is not well known.Objective: To determine the skeletal impact of chronic treatment with rPTH (1–34) in patients with hypoparathyroidism.Design: Single-center prospective study. Patients trea...

Background: Osilodrostat is a potent oral inhibitor of the adrenal enzymes aldosterone synthase and 11b-hydroxylase and decreases glucocorticoid and mineralocorticoid production and secretion. Phase 2 and 3 studies from the osilodrostat clinical trial programme have demonstrated the drug’s efficacy and safety in patients with Cushing’s disease. Osilodrostat received European Marketing Authorization (MA) for the treatment of Cushing’s syndrome (CS) in adults....